These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 6112473)
1. "Morning after pill" and antithrombin III. Weenink GH; Ten Cate JW; Kahlé LH; Lamping RJ; Treffers PE Lancet; 1981 May; 1(8229):1105. PubMed ID: 6112473 [TBL] [Abstract][Full Text] [Related]
2. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Weenink GH; Kahlé LH; Lamping RJ; ten Cate JW; Treffers PE Acta Obstet Gynecol Scand; 1984; 63(1):57-61. PubMed ID: 6720257 [TBL] [Abstract][Full Text] [Related]
3. "Morning-after pill" and antithrombin III. Weenink GH; ten Cate JW; Kahle LH; Lamping RJ; Treffers PE Acta Obstet Gynecol Scand; 1983; 62(4):359-63. PubMed ID: 6637410 [TBL] [Abstract][Full Text] [Related]
4. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. Robinson GE; Burren T; Mackie IJ; Bounds W; Walshe K; Faint R; Guillebaud J; Machin SJ BMJ; 1991 Feb; 302(6771):269-71. PubMed ID: 1998792 [TBL] [Abstract][Full Text] [Related]
5. [Studies on inhibitors of blood coagulation and fibrinolysis during use of oral contraceptives]. Miyaji K Nihon Funin Gakkai Zasshi; 1982 Apr; 27(2):242-50. PubMed ID: 12158577 [TBL] [Abstract][Full Text] [Related]
7. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369 [TBL] [Abstract][Full Text] [Related]
8. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629 [TBL] [Abstract][Full Text] [Related]
9. Estrogens: why harmless as menopausal therapy but hazardous in the "Pill"? Edwards CC; Drill VA JAMA; 1971 Jan; 215(3):(3): 492-493. PubMed ID: 12332746 [TBL] [Abstract][Full Text] [Related]
10. Oestriol deficiency, a possible factor in the aetiology of thrombo-embolism in pill users. Zaki K; Sami G; Nour H Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):19-24. PubMed ID: 12256026 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. Webb AM; Russell J; Elstein M BMJ; 1992 Oct; 305(6859):927-31. PubMed ID: 1458074 [TBL] [Abstract][Full Text] [Related]
13. Levels of protein S during the normal menstrual cycle and in women on oral contraceptives low in estrogen. Jespersen J; Nielsen MT Gynecol Obstet Invest; 1989; 28(2):82-6. PubMed ID: 2529199 [TBL] [Abstract][Full Text] [Related]
17. [Clinical data on the use of current oral contraceptives]. Krymskaia ML; Khomasuridze AG Akush Ginekol (Mosk); 1983 Nov; (11):19-22. PubMed ID: 6666790 [TBL] [Abstract][Full Text] [Related]
19. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162 [TBL] [Abstract][Full Text] [Related]
20. Effect on blood coagulation and fibrinolysis in women using norethisterone or a combination of ethinyloestradiol and quingestianol. Korsan-Bengtsen K; Larsson B Gynecol Obstet Invest; 1978; 9(6):312-8. PubMed ID: 754993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]